Titel: 3rd Annual Business of Targeted Therapeutics Executive Summit

Termin: 15.6.2006, 8:00 Uhr, bis 16.6.2006, 19:30 Uhr

Veranstaltungsort:
Westin Grand Hotel
2350 M Street, NW
Washington, DC 20037
USA

Referenten: Dr Mark Chang (Member of Strategic Decisions Group’s Life Sciences Practice) *** Dr William Leaf-Herrmann (Member of Strategic Decisions Group’s Life Sciences Practice) *** Duncan John, Senior (Member of Strategic Decisions Group’s Life Sciences Practice) *** Michael N. Liebman, Ph.D. (Executive Director, Windber Research Institute) *** Nadine Cohen, Ph.D. (Head of Pharmacogenomics, Johnson&Johnson Pharmaceutical Research and Development East Coast and Europe) *** Vincenzo Libri, MD, Ph.D. (Medical Director and Head of Exploratory Medical Science, CPDM & NGI CEDD, GlaxoSmithKline) *** Gene Williams (CEO, Cambridge Healthtech Associates) *** Cheryl L. Marks, Ph.D. (Associate Director, Division of Cancer Biology, Program Director, Mouse Models of Human Cancers Consortium, National Cancer Institute) *** Derek Hodkey (Chief Operating Officer & General Manager, Pathways, Cambridge Healthtech Associates) *** Michael Stocum, Ph.D. (Managing Director, Personalized Medicine Partners) *** Malorye Branca (Editor-in-Chief, Pharmaceutical Discovery)

Weitere Informationen:
http://www.healthtech.com/2006/bdx/

Kurzbeschreibung: The fundamentals of the pharmaceutical industry are certainly changing. Although the historic model of blockbuster drugs is not becoming extinct, the days of profitability based solely on these blockbusters is showing its age. The traditional strategy must be combined with a model based on targeted therapeutics in order for profitability to continue. This event in its third year focuses on the key issues surrounding personalized medicine and companion diagnostics such as:

* The Overall Effects of Changing the Pharmaceutical Model from Blockbuster to Targeted Therapeutics

* Competing and Profiting with the New Strategic Model

* The Impact of Targeted Therapeutics on CRO's and Clinical Trials

* Impact for Marketing - New Strategies and Thought Processes

* Impact on R&D Strategy Development: Need for New Forecasting and Projection Strategies

* The Regulatory Perspectives on Pharmacogenomic Applications

* How Payors and Providers Factor-in to the Equation

Participants include vice presidents, directors and managers in strategic marketing, licensing, genomics, strategic planning, business development, research & development, pharmacogenomics, business affairs, regulatory affairs, reimbursement and pricing, new product planning and diagnostics.

Kontakt: Mrs Nicole Roberts
Cambridge Healthtech Institute
Pharmaceutical Strategy Series
1037 Chestnut Street
Newton Upper Falls, MA 02464
USA
Tel.: +1 - 617 - 6 30 13 42
Fax: +1 - 617 - 6 30 13 25
nroberts@pharmaseries.com
http://www.healthtech.com/

Veranstalter: Cambridge Healthtech Institute - Pharmaceutical Strategy Series

Schlagworte: Genetische Tests/Beratung, Genforschung/-technik, Genomanalyse, Gentherapie, Krankheit, Pharmazeutik